Search This Blog

Wednesday, July 31, 2019

Apple services, wearables shore up results as iPhone falls below half of sales

 Apple Inc iPhone sales dropped to less than half of quarterly revenue for the first time in seven years, but CEO Tim Cook on Tuesday described the change as successfully diversifying away from a single product and forecast results above Wall Street targets.

That strategy proved especially useful in China, the world’s largest smartphone market. Investors feared a drumbeat of negative shipment data from the Chinese government and analysts meant problems for the iPhone maker.
Apple’s greater China sales, which had gone into a near free fall earlier this year, dipped only slightly, assuaging concerns that trade tension were undermining Apple’s standing in one of its most important markets. Shares rose 4.25% after hours.
Moribund global mobile phone sales have led Apple to focus on accessories like the Apple Watch and growth in music, apps, gaming, video and a credit card coming in August. In mainland China, Cook said the overall number of Apple device users had grown in the fiscal third quarter, helping to increase the market for its services, whose sales were up by more than 10% there.
“We actually grew in mainland China,” Cook told Reuters. “Non-iPhone revenue grew 17%. We grew in every category outside of iPhone.”
But globally, iPhone sales fell 12% to $25.99 billion, after dropping 17% in the previous quarter, and matched Wall Street targets.
Wearables and other accessories revenue rose nearly 50%, topping expectations.
Services revenue rose 12.6% to $11.46 billion, slowing and slightly missing expectations but setting a new record.
Apple said it expects revenue for the current fiscal fourth quarter of between $61 billion and $64 billion, compared with analyst estimates of $61.02 billion. At the high end of Apple’s forecasted range, sales would beat the prior year’s $62.90 billion in sales, despite the fact that analysts expected continued lackluster iPhone sales until 5G models arrive in 2020.
For the fiscal third quarter ended in June, Apple reported a 1% rise in revenue to $53.8 billion and a 7% drop in earnings per share to $2.18, compared with expectations of $53.39 billion and $2.10 per share, according to Refinitiv data.
Hal Eddins, chief economist for Apple shareholder Capital Investment Counsel, said he was pleasantly surprised to see iPhone sales declines slow down versus the prior quarter.
“You really don’t hear people talk about their phones like they did several years ago,” Eddins said. But, “the key is that when people want to splurge on a phone, they do it with an Apple product.”
Apple did not give the number of active Apple devices, but in January it said it was 1.4 billion, with 900 million of those being iPhones. Investors used the number, called the installed base, as a proxy for how many subscribers it can gain for its services business. Cook told investors on a conference call Tuesday that Apple has 420 million paid subscribers to its own services and third-party apps. The company has set a goal of 500 million by 2020.
Trip Miller, managing partner at Apple shareholder Gullane Capital Partners, said he wants to see services growth return to the 20% range and thinks Apple needs to use its billions in cash to buy media properties to fuel its forthcoming television service.
“You have to have a bigger installed base and have services that people get value from,” Miller said.
TRADE TENSION STILL LOOMS LARGE
Apple reported results as U.S. and Chinese trade negotiators resumed off-and-on talks. U.S. President Donald Trump has suspended new tariffs on a final $300 billion of Chinese imports, which would include iPhones.
Trade tension has slowed down economic growth in China, a major market for Apple, which effectively cut iPhone prices in China earlier this year after currency exchange rates had made its phones too expensive for many Chinese consumers.
Apple’s market share in China declined to 5.8% from 6.4%, according to market research firm Canalys, in part because smartphone rival Huawei Technologies Co Ltd gained market share to become the top handset seller in the country.
But Apple experienced a smaller market share loss than competitors such as Xiaomi Corp, Oppo and Vivo, according to Canalys data. Cook said that iPhone price adjustments, plus the Chinese government’s move to cut phone taxes, helped keep iPhone sales in China from eroding further.
“Our trade-in and financing programs are doing extremely well in China,” Cook told Reuters. “Because of the active installed base is growing in China, our services business is doing very well, growing double digits.”
Apple shares have gained more than 20% since early June, when shares dropped on news that the U.S. Department of Justice had jurisdiction over the company in a potential probe as part of a broader review of whether technology giants engage in anticompetitive practices.
Apple said revenue for its “Wearables, home and accessories” segment that contains devices like the Apple Watch and AirPods was $5.53 billion, compared with analyst estimates of $4.81 billion.
Apple said it returned more than $21 billion to shareholders during the fiscal third quarter, including $17 billion in share repurchases. It declared a dividend of 77 cents per share.

United Therapeutics EPS beats by $0.89, beats on revenue

United Therapeutics (NASDAQ:UTHR): Q2 Non-GAAP EPS of $3.63 beats by $0.89; GAAP EPS of $4.66 beats by $2.20.
Revenue of $373.6M (-16.0% Y/Y) beats by $41.34M.

LivaNova PLC EPS beats by $0.05, beats on revenue

LivaNova PLC (NASDAQ:LIVN): Q2 Non-GAAP EPS of $0.70 beats by $0.05; GAAP EPS of -$0.61.
Revenue of $277.2M (-3.6% Y/Y) beats by $2.06M.

FDA OKs Bayer Nubeqa for non-metastatic prostate cancer

The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).1 The FDA approval is based on the Phase III ARAMIS trial evaluating Nubeqa plus androgen deprivation therapy (ADT), which demonstrated a highly significant improvement in the primary efficacy endpoint of metastasis-free survival (MFS), with a median of 40.4 months versus 18.4 months for placebo plus ADT (p<0.0001).1 MFS is defined as the time from randomization to the time of first evidence of blinded independent central review (BICR)-confirmed distant metastasis or death from any cause within 33 weeks after the last evaluable scan, whichever occurred first. Nubeqa was approved under the FDA’s Priority Review designation, which is reserved for medicines that may provide significant improvements in the safety or effectiveness of the treatment for serious conditions.
“Patients at this stage of prostate cancer typically don’t have symptoms of the disease. The overarching goals of treatment in this setting are to delay the spread of prostate cancer and limit the burdensome side effects of therapy,” said Matthew Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center. “This approval marks an important new option for the prostate cancer community.”
In the U.S., over 73,000 men are estimated to be diagnosed with castration-resistant prostate cancer (CRPC) in 2019. About 40 percent of these patients have prostate cancer that has not spread to other parts of the body and is also associated with a rising prostate-specific antigen (PSA) level, despite a castrate testosterone level, which is known as nmCRPC. This is important because about one-third of men with nmCRPC go on to develop metastases within two years. PSA monitoring is important to identify patients and help offset undertreatment in men before the disease spreads.

Smith & Nephew reported revenue increase

Smith & Nephew’s underlying revenue grew 3.5% in the quarter ending 29 June 2019, with emerging markets recording strong mid-teen growth. During the first half of FY 2019, the business’ trading profit margin improved 60bps to 21.4%, while the operating profit margin expanded 150bps to 16.8%. Cash generated from operations grew YoY to $543m from $418m over the same period.
China steered revenue growth in emerging markets, recording more than 30% growth. Factoring in its robust performance, the company upgraded its full-year revenue guidance by 50bps to 4%, but kept the trading profit margin guidance unchanged.
Namal Nawana, CEO of Smith & Nephew, said: “Organic revenue growth has been solid across all three franchises, with strong performance in Emerging Markets and global Sports Medicine. At the same time, we expanded our margin.”

Roche, Spark extend $4.3B takeover again

Roche (OTCQX:RHHBY) and Spark Therapeutics (NASDAQ:ONCE) have announced another extension of the Swiss drugmaker’s $4.3B takeover offer for the U.S. gene therapy specialist as regulatory reviews in the U.S. and Britain continue.
The offer for Spark shares now runs to Sept. 3, Roche said, adding terms and conditions are unchanged.
“The parties remain committed to the transaction and are working cooperatively and expeditiously with the Federal Trade Commission and UK Competition and Markets Authority.”

Takeda Pharmaceutical reports Q1 results

Takeda Pharmaceutical (OTCPK:TKPHF): Q1 Non-GAAP EPS of ¥128.00; GAAP EPS of -¥13.00.
Revenue of ¥849.1B (+88.7% Y/Y)